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ABSTRACT 24 
This study reports the development of several cloning vectors for bifidobacteria 25 
based on the replicon of pBC1, a cryptic plasmid from Bifidobacterium catenulatum 26 
L48 thought to replicate via the theta mode. These vectors, in which antibiotic 27 
resistance genes encoding either erythromycin or tetracycline resistance acted as 28 
selection markers, were able to replicate in a series of eight Bifidobacterium species at 29 
frequencies ranging from 4.0x101 to 1.0x105 transformants µg-1, but not in Lactococcus 30 
lactis or Lactobacillus casei. They showed a relative copy number of around 30 31 
molecules per chromosome equivalent, and a good segregational stability, with more 32 
than 95% of the cells retaining the vectors after 80-100 generations in the absence of 33 
selection. Vectors contain multiple cloning sites of different length, and the lacZα 34 
peptide gene was introduced in one of the molecules, thus allowing easy selection of 35 
colonies harboring recombinant plasmids in Escherichia coli. The functionality of the 36 
vectors for engineering Bifidobacterium strains was assessed by cloning and examining 37 
the expression of an α-L-arabinofuranosidase gene belonging to Bifidobacterium 38 
longum. E. coli and Bifidobacterium pseudocatenulatum recombinant clones were stable 39 
and showed an increase in α-arabinofuranosidase activity of over 100-fold compared to 40 
the untransformed hosts. 41 
 42 
INTRODUCTION 43 
Bifidobacterium species are among the dominant microbial populations of the 44 
gastrointestinal tract (GIT) of humans and other mammals (8, 33), where they are 45 
considered to exert many beneficial health effects (for a review see 19) including the 46 
establishment of a healthy microbiota in infants, the development of a competent 47 
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immune system, the production of short chain fatty acids, and the inhibition of 48 
pathogens (19, 45). Not surprisingly, bifidobacteria are major components of many 49 
commercial probiotic products that have been shown effective in alleviating 50 
constipation, reducing the symptoms of lactose intolerance, enhancing immune 51 
functions, reducing cholesterol levels, and the suppression of tumorigenesis (19, 29). 52 
Unfortunately, our basic knowledge of the mechanisms by which bifidobacteria 53 
interact and communicate with other bacteria and host cells remains poorly understood. 54 
Such knowledge is essential for the scientific support of their purported health benefits 55 
and their rational inclusion as probiotics in functional foods (19), but the study of these 56 
organisms’ probiotic properties and their contribution to host health and well-being has 57 
been hampered by a lack of molecular tools (50). In addition, the study of the variables 58 
affecting the transformation of plasmid DNA in Bifidobacterium species, and the 59 
optimization of the transformation process, have only rarely been addressed (3, 36, 37). 60 
Bifidobacteria belong to the phylum Actinomycetaceae -Gram-positive microorganisms 61 
with high G+C content that have complex nutritional requirements and which are very 62 
sensitive to oxygen (41); these characteristics (strict anaerobes, nutritionally fastidious, 63 
and instable DNA cloning in Escherichia coli) may have limited the study of their 64 
genetics. 65 
Recently, the genome sequences of Bifidobacterium longum NCC 2705 (42), B. 66 
longum DJO10A (NZ_AABM00000000), B. adolescentis ATCC 15703 (NC_008618) 67 
and B. adolescentis L2–32 (NZ_AXD02000000) have been released, providing a vast 68 
array of genetic data which may help us better understand the mode of action behind 69 
their probiotic properties (15). However, the genomic data available cannot be fully 70 
exploited due to the limitations of our current molecular tools for the analysis of gene 71 
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function and regulation. Therefore, new, improved vectors for cloning, integration, 72 
knockout and gene expression studies are required. Molecular studies are also required 73 
for the future improvement of Bifidobacterium strains by genetic engineering, i.e., the 74 
construction of strains with enhanced probiotic characteristics and/or that better retain 75 
their viability during storage. Furthermore, bifidobacteria are thought to be promising 76 
systems for the delivery of therapeutic agents, such as antigens (for live vaccine 77 
development) and tumor-suppressing substances (10, 53), and as a means of increasing 78 
beneficial detoxifying activities (31). 79 
Until recently, only fragmentary information on the bacteriophages infecting 80 
Bifidobacterium species was available (44). Moreover, phages infecting bifidobacteria 81 
have never been isolated and characterized. Indeed, genome sequencing has only 82 
identified a single related prophage-like element in each of the genomes of the 83 
sequenced strains B. breve UCC 2003 (not yet released), B. longum NCC 2705 and B. 84 
longum DJO10A (51). Thus, bifidobacterial plasmids are the only available source of 85 
replicons for bifidobacterial vectors. Extrachromosomal elements seem not to be very 86 
common among Bifidobacterium strains (43). Nonetheless, 14 fully-sequenced plasmids 87 
from eight bifidobacterial species are reported in the GenBank database 88 
(http://www.ncbi.nlm.nih.gov/sites/entrez). However, the basic biology of plasmids in 89 
this genus remains poorly understood; indeed, in only a few has the mode of replication 90 
been analyzed (4, 21, 27, 30, 32). Further, the dissection of the open reading frames 91 
(ORFs) and the analysis of untranslated sequences and structures has been undertaken 92 
in only a couple of plasmids (2, 5). In spite of this, a bunch of all-purpose and specific 93 
vectors have already been constructed and used in different studies. As an example, 94 
pMDY23, a reporter vector, carries the gusA gene of E. coli (18); vector pBES2 has 95 
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been used to express the α-amylase gene of B. adolescentis in B. longum (34); 96 
pBLES100 (25) has been used in tumor suppressor studies (54) and for the expression 97 
of the flagellum protein gene(s) of Salmonella (for mucosal immunization purposes) 98 
(46); and pBV22210 has been used to express and deliver the anti-cancer protein 99 
endostatin in cancer gene therapy (53). 100 
The present study reports on the further characterization of plasmid pBC1 from B. 101 
catenulatum L48 (1, 2) and its use in the development of improved cloning vectors. The 102 
plasmid has already been cloned entirely in a pUC derivative in a previous work (1). 103 
Furthermore, the pUC part of the resulting shuttle vector was removed, demonstrating 104 
that necessary replicating elements were all within the pBC1 DNA (1). These two 105 
constructs can be considered true cloning vectors because they have several unique 106 
restriction enzyme sites at non-essential positions in their sequences and antibiotic 107 
resistance genes allowing selection. In this work, the construction of a series of new E. 108 
coli-Bifidobacterium shuttle vectors is reported. These include the replacement of the 109 
erythromycin resistance gene by a tetracycline resistance gene of bifidobacterial origin, 110 
the insertion of a large polylinker, and the cloning of the α-galactosidase 111 
complementing-peptide gene for a convenient blue-white screening of recombinant 112 
clones in E. coli. The study of copy number, stability and host range of some vectors 113 
was also addressed. To check the functionality of these vectors, an α-L-114 
arabinofuranosidase gene from B. longum B667 was cloned and overexpressed in both 115 
E. coli and Bifidobacterium strains. 116 
 117 
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MATERIAL AND METHODS 118 
Bacterial strains, plasmids and growth conditions. The bacterial strains and 119 
plasmids used in this study are listed in Table 1. Bifidobacteria, lactobacilli and 120 
Pediococcus acidilactici strains were routinely cultivated under anaerobic conditions at 121 
37ºC in MRS broth (Merck; VWR International, Darmstad, Germany) or in RCM broth 122 
(Merck; VWR International, Darmstad, Germany), supplemented with 0.25% (w/v) L-123 
cysteine (MRSC). Lactococcus and Enterococcus strains in Table 2 were grown in M17 124 
(Scharlau, Scharlau Chemie SA, Barcelona, Spain). E. coli and Corynebacterium 125 
glutamicum strains were grown at 37ºC in Luria Bertani (LB) broth (38) with vigorous 126 
shaking. 127 
Antibiotics (supplied by Sigma, Sigma Chemical Co., St. Louis, MO) were added to 128 
the appropriate media at the following concentrations: ampicillin 100 µg ml-1, 129 
erythromycin 250 µg ml-1 and tetracycline 5 µg ml-1 for E. coli; erythromycin 5 µg ml-1, 130 
tetracycline 5 µg ml-1 and chloramphenicol 2 µg ml-1 for bifidobacteria. 131 
DNA isolation and analysis. Plasmid DNA from bifidobacteria was isolated by the 132 
method of O’Sullivan and Klaenhammer (28) with the following modification: pellets 133 
were suspended in TSE buffer (sucrose 25%, 50 mM Tris-HCl, 10 mM EDTA, pH 8.0) 134 
and incubated with lysozyme (30 mg/ml) at 37ºC for 30 min. Plasmid DNA from E. coli 135 
was isolated using the commercial Plasmid Miniprep Kit (Eppendorf AG, Hamburg, 136 
Germany), following the manufacturer’s recommendations. Plasmids were analyzed by 137 
electrophoresis in TBE (89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA, pH 8.0) on 138 
0.75-1.2% agarose gels (FMC Bioproducts, Philadelphia, PA), and then stained with 139 
ethidium bromide (0.5 µg ml-1) and photographed. 140 
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Total DNA from the B. longum B667 was prepared according to the procedure of 141 
Tanaka et al. (47), and analyzed as above. 142 
DNA manipulation and molecular techniques. The general procedures used for 143 
DNA manipulation were essentially those described by Sambrook and Russell (38). 144 
Restriction endonucleases and Taq DNA polymerase came from Takara (Takara, Otsu, 145 
Shiga, Japan), T4 DNA ligase from Invitrogen (Invitrogen, Carlsbad, CA), and the 146 
Klenow fragment of E. coli polymerase I from Roche (Roche Applied Sciences, Basel, 147 
Switzerland). All were used according to the manufacturers’ instructions. Amplicons 148 
were purified by using the GFX PCR DNA Gel Band Purification kit (GE Healthcare 149 
Biosciences, Buckinghamshire, UK). When required, purified plasmids and amplicons 150 
were sequenced by cycle extension in an ABI 370 DNA sequencer (Applied 151 
Biosystems, Foster City, CA, USA). 152 
Plasmid transfer. Plasmids were introduced into E. coli DH5α electrocompetent 153 
cells by electrotransformation (electroporation) (38) using a Gene-Pulser Apparatus 154 
(Bio-Rad Laboratories, Richmond, CA) according to the manufacturer’s instructions. 155 
Electroporation of lactic acid bacteria strains (Lactococcus lactis, Lactobacillus casei 156 
and Enterococcus durans) was essentially done as reported by Leenhouts et al. (22), 157 
using as a positive control plasmid p210 from L. lactis (39). Corynebacterium 158 
glutamicum and Pediococcus acidilactici strains were electrotransformed as previously 159 
reported (49). Electrocompetent Bifidobacterium cells were prepared by optimizing 160 
previously reported methods (1, 2). In short, fresh MRSC broth (50 ml) was inoculated 161 
with an overnight culture (8% inoculum) of the bifidobacterial strain and incubated at 162 
37ºC for 3-4 h until the culture reached an OD600 nm of 0.5-0.7. The cells were then 163 
chilled for 20 min, washed twice in ice-cold sucrose-citrate buffer (0.5 M sucrose, 1 164 
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mM ammonium citrate, pH 5.8) and suspended in 100 µl of the same buffer. The cell 165 
suspension was stored on ice for 20 min. Electroporation was performed under the 166 
following conditions: 25 µF, 200 Ω and 10 kV. The cells were immediately diluted in 167 
950 µl of RCM and incubated for 2.5 h before plating onto the same agarified medium 168 
with the appropriate antibiotic. Plates were incubated for 2-3 days at 37ºC under 169 
anaerobic conditions. 170 
Detection of ssDNA intermediates by hybridization. Total DNA from 171 
Bifidobacterium and E. coli cells grown in the presence or absence of both 172 
chloramphenicol and rifampicin was isolated essentially as described by te Riele et al. 173 
(48). The DNA was electrophoresed in a 0.7% agarose gel, and transferred under 174 
denaturing and non-denaturing conditions to Hybond-N nylon membranes (Amersham 175 
Biosciences, Uppsala, Sweden). ssDNA intermediates were detected by hybridization 176 
using pBM02-derived and pBC1-derived DNA probes internally labeled with [α-177 
32P]dCTP (GE Healthcare). 178 
Segregation stability of vectors in bifidobacteria. The stability of the constructs 179 
was assayed by growing the cells in non-selective media for approximately 100 180 
generations and plating daily onto non-selective agar plates. Antibiotic resistance 181 
maintenance was monitored by transference of the resulting colonies to antibiotic-182 
containing agar plates. Finally, plasmids was monitored by plasmid extraction from 183 
antibiotic resistant and susceptible colonies as above. 184 
Antibiotic resistance of the vectors. The minimum inhibitory concentration (MIC) 185 
of erythromycin and tetracycline supported by the constructs in different hosts was 186 
measured by the Etest method, according to the manufacturer’s instructions (AB 187 
Biodisk, Solna, Sweden). MIC assays were performed in LSM medium (90% 188 
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Isosensitest, 10% MRS; both from Oxoid, Oxoid Ltd., Basingstoke, Hampshire, UK) 189 
with cysteine (0.3 g l−1) as previously reported (17). 190 
Determination of the relative plasmid copy number. The relative copy number of 191 
the pBC1-derived vectors was assessed by quantitative real-time PCR (QPCR), using 192 
the culture and PCR conditions reported by Lee et al. (20). Amplification and detection 193 
were performed in a Fast Real-Time PCR system (Applied Biosystems, Foster City, 194 
CA) using Power SYBER® Green PCR Master Mix (Applied Biosystems). The FrepB 195 
and RrepB primers (Table 1) were designed based on the pBC1 repB sequence (in 196 
which their oligonucleotide sequences were 113 bp apart). The xylulose-5-phosphate-197 
fructose-6-phosphate-phosphoketolase gene (xfp) (GenBank Accession No. AY377401) 198 
of B. pseudocatenulatum M115 was used as the single-copy reference gene. A 120 bp 199 
segment of the xfp gene was amplified with primers Fxfp and Rxfp (Table 1). The 200 
relative copy number of the derivatives was calculated using the formula Nrelativa=(1+E)-201 
∆CT
 (19), where E is the amplification efficiency of the target and reference genes, and 202 
∆CT is the difference between the threshold cycle number (CT) of the xfp reaction and 203 
that of repB. Experiments were performed in triplicate; mean results are provided. 204 
Cloning and expression of an α-L-arabinofuranosidase gene from B. longum. 205 
The α-L-arabinofuranosidase gene (abfB) in the B. longum B667 strain has been 206 
characterized by Margolles and de los Reyes-Gavilán (24). Amplification of the abfB 207 
gene was accomplished with primers abfBF and abfBR, in which SphI and PstI sites 208 
were inserted, using genomic DNA from B. longum B667 as a template. The PCR 209 
product was purified, digested with SphI and PstI, cloned into pAM1 digested with 210 
these two enzymes, and ligated overnight at 12ºC. The ligation mixture was 211 
electrotransfomed into E. coli DH11S, in which the construct (pAM-abfB) was obtained 212 
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(it proved to be not viable in E. coli TOP10) and verified by the use of restriction 213 
enzymes and sequencing. pAM-abfB was then transferred by electroporation into B. 214 
pseudocatenulatum M115 cells. 215 
Determination of α-L-arabinofuranosidase activity. α-L-arabinofuranosidase 216 
activity in the cloning hosts and recombinant cells was determined according to 217 
Gueimonde et al. (11). Briefly, pellets were suspended in 2 ml of potassium phosphate 218 
buffer (pH 6.8) and the cells disrupted with a Cell Disruptor (Constant Systems Ltd., 219 
Daventry, Northants, UK). Activity was measured in triplicate using independent cell-220 
free extracts. 221 
 222 
RESULTS 223 
 224 
Construction of vectors based on the pBC1 replicon. The pAM1 shuttle vector 225 
resulting for the cloning of pBC1 in pUC19E (1) was taken at the starting material for 226 
the construction of more versatile pBC1-derived vectors. Firstly, the heterologous 227 
erythromycin resistance gene in pAM1, originally isolated from the Staphylococcus 228 
aureus plasmid pE194 (14), was replaced by a recently characterized tet(W) gene 229 
identified in an intestinal isolate of B. longum (9). A 2467 bp segment of DNA 230 
including the tet(W) gene and its upstream promoter sequences was amplified by PCR 231 
with specific primers, into which the SacI sites were incorporated. The tet(W) gene was 232 
inserted into the unique SacI site of pAM1. The new construct, pAM3 (Fig. 1), was 233 
recovered in E. coli and then transformed into B. pseudocatenulatum. The erythromycin 234 
resistance gene of pAM3 was finally removed (to give pAM4, Fig. 1) by partial 235 
digestion with SalI, isolation of the right fragment from an agarose gel, intramolecular 236 
ligation and electroporation of the ligation mixture into E. coli. The new construct was 237 
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finally electrotransformed in B. pseudocatenulatum and other bifidobacteria. New single 238 
restriction enzyme sites were introduced in pAM4 by cloning the 28 unique recognition 239 
sequences from the multiple cloning site (MCS) of pUK21 (52). The MCS was 240 
recovered from a gel after digestion of pUK21 with SpeI and then ligated to pAM4 241 
digested with XbaI. As usual, the construct was firstly obtained in E. coli, checked by 242 
restriction enzyme analysis and sequenced. Following electroporation, the new 243 
construct, pAM5, was then recovered from bifidobacterial strains. 244 
For convenient blue/white screening of recombinant molecules in E. coli, we 245 
restored the original lacZα-peptide gene, disrupted in pUC19E (23), in a pAM1 246 
derivative. To this end, a 327-bp segment from pUC19 (55), carrying the lacZα gene 247 
and the MCS, was amplified with primers LacZF and LacZR (Table 1), purified, and 248 
cloned into the pCR®4-TOPO vector. The construct was then digested with the 249 
restriction enzyme NotI and treated with the Klenow fragment of the E. coli polymerase 250 
I to make blunt ends. After inactivation of Klenow, the plasmid was digested once again 251 
with SpeI. The resulting fragment was purified from a gel and ligated to a pAM1 vector 252 
subjected to a similar process of digestion with HindIII, treatment with Klenow, and 253 
subsequent digestion with XbaI (Fig. 1). The construct, pAM6, was first identified in E. 254 
coli, verified by sequencing and introduced in B. pseudocatenulatum M115, to check for 255 
replication in bifidobacteria. 256 
Construct host range, antibiotic resistance, copy number and stability. To study 257 
the host range of the pBC1 derivatives, competent cells belonging to strains of eight 258 
different Bifidobacterium species (B. adolescentis, B. animalis, B. breve, B. dentium, B. 259 
longum, B. pseudolongum, B. pseudocatenulatum, and B. thermophilum) were 260 
electrotransformed with one µg of a unique DNA sample from pAM4. Transformants 261 
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were recovered for all eight species with the two vectors, although the frequencies 262 
ranged from 4.0x101 µg-1 in B. animalis LMG 10508 to 1.0x105 in B. 263 
pseudocatenulatum M115 (Table 2). Transformation was found to be strain-dependent 264 
rather than species-dependent, as different strains of the same species showed dissimilar 265 
transformation frequencies of more than two log10 units (data not shown). At low 266 
frequency, pBM4 was also shown to transform the strain Corynebacterium glutamicum 267 
LMG 19741. However, using the same amount of DNA, transformant colonies of 268 
several lactic acid bacteria strains of our laboratory collection, belonging to Lactococcus 269 
lactis, Lactobacillus casei and Enterococcus durans species, were never recovered 270 
(Table 2). Transformants were neither obtained for the strain Propionibacterium 271 
acidilactici LMG 11384. Finally, pAM2 (a pBC1-derived construct lacking the pUC 272 
part) (1) was used to transform electrocompetent cells of E. coli, but transformants were 273 
not recovered, therefore the pBC1 replicon was assumed incapable of replicating in this 274 
species. 275 
The MIC resistance values (obtained by the Etest method) for erythromycin and 276 
tetracycline conferred upon B. pseudocatenulatum M115 by pAM1 and pAM4 vectors 277 
were 8-12 µg ml-1 and 48 µg ml-1 respectively. These values contrast with the high 278 
susceptibility shown by the original plasmid-free M115 strain (0.064 and 0.125 µg ml-1 279 
respectively). 280 
pBC1 and pAM1 copy number has already been established to be around 30 copies 281 
per chromosome equivalent in B. pseudocatenulatum M115 (1). In a similar way, the 282 
copy number of pAM5 and pAM6 in this strain was shown to be of 31.5±0.37 and 283 
28.4±0.64, respectively. Copy number for these two vectors in B. breve UCC2003 was 284 
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estimated in 29.1±0.96 and 27.6±0.54, respectively, per cell. These results agree well 285 
with those reported previously (1, 2). 286 
Constructs pAM2 and pAM4 were both checked for stability under non-selective 287 
conditions in B. pseudocatenulatum M115. Twenty four colonies of both antibiotic 288 
resistant and susceptible phenotype were examined for plasmid maintenance after five 289 
overnight transfers (approximately 80-100 generations). All antibiotic resistant colonies 290 
retained the constructs, while antibiotic susceptible were shown to be plasmid free. 291 
Based on these data, more than 96% and 98% of the colonies retained the pAM2 and 292 
pAM4 constructs respectively. Similar stability frequency for these two constructs was 293 
observed in B. longum L25 and B. animalis LMG 10508 (data not shown). 294 
Analysis of the intracellular presence of pBC1 ssDNA. Comparisons of pBC1 295 
translated and untranslated sequences with those in databases suggests that pBC1 might 296 
replicate by a theta type mechanism, although elements of both the theta and rolling 297 
circle (RC) type mechanisms have been reported in pBC1 (1). To gain further insight 298 
into its mode of replication, and on the involvement of the RNA polymerase in this 299 
process, the whole pBC1 plasmid and its derivatives pBC1.5 (lacking the putative 300 
promoter region of a copG-like gene) and pBC1.2 (lacking both copG-like and orfX-like 301 
genes; 1) were analyzed by hybridization using an internal segment of repB from pBC1 302 
(obtained by PCR) as a probe. As a positive control of RC replication (in which ssDNA 303 
appears as a replication intermediate), a derivative of plasmid pBM02 from Lactococcus 304 
lactis -p210- (39) was run under the same conditions. Comparison of the hybridization 305 
results of gels transferred under denaturing and non-denaturing conditions can be found 306 
in Fig. 2. As expected, ssDNA accumulated in the samples corresponding to p210 307 
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treated with both chloramphenicol and rifampicin (Fig. 2, line 8 in panels B and D), but 308 
no such DNA was seen in samples involving pBC1 or its derivatives. 309 
Cloning and expression of a α-L-arabinofuranosidase gene from B. longum. To 310 
demonstrate the functionality of pBC1-derived vectors, the abfB gene encoding an α-L-311 
arabinofuranosidase from B. longum B667 (24) was cloned in both B. 312 
pseudocatenulatum and E. coli and its expression assessed. The abfB gene from this 313 
strain and its regulatory sequences were amplified from purified total DNA of B. 314 
longum B667 using two primers with added SphI and PstI sites (Table 1). This allowed 315 
directional cloning in pAM1 digested with these two enzymes (Fig. 3). The construct, 316 
pAM-abfB, was obtained in E. coli DH11S and was subjected to restriction enzyme 317 
analysis and sequencing before its electrotransformation into B. pseudocatenulatum 318 
M115. These two strains might have equivalent genes to abfB, but they show negligible 319 
expression in the absence of plasmid (< 0.12 specific activity units [SAU; min-1µg 320 
protein-1]). In contrast, in the E. coli and B. pseudocatenulatum clones harboring the 321 
abfB gene of B. longum B667, the α-arabinofuranosidase activity ranged from 9.45 to 322 
16.15 SAUs (average 12.95), an increase of more than 100-fold. Moreover, no 323 
segregant lost this activity after a week of daily transferring the B. pseudocatenulatum 324 
strain in non-selective conditions. Indeed, all 24 colonies examined by plasmid analysis 325 
retained the pAM-abfB construct, thus considering it was therefore stable in this host. 326 
 327 
DISCUSSION 328 
The lack of suitable tools for use in bifidobacteria for cloning, integration, gene 329 
disruption and gene expression analysis is delaying the analysis of their gene-related 330 
functions and the molecular mechanisms underlying their probiotic properties -and such 331 
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tools will be necessary if we are to exploit the potential of the vast array of data 332 
provided by genome sequencing projects. In this work, pAM1, a previously developed 333 
E. coli-Bifidobacterium shuttle vector harboring the pBC1 replicon (1), was modified to 334 
produce a new series of pBC1-derived vectors, giving versatility and adding new 335 
possibilities for cloning and expression in bifidobacteria. Maintaining of the whole 336 
plasmid was based on the observation that, although repB is the only gene considered 337 
essential for pBC1 replication, orfX-like and copG-like genes influence the stability and 338 
copy number of the constructs in at least some strains (1, 2). 339 
At present, several Bifidobacterium-E. coli shuttle vectors have been constructed 340 
that exploit cryptic plasmids in a procedure similar to that followed in this study. These 341 
included, among others, general E. coli-Bifidobacterium shuttle vectors (1, 5, 18, 21, 25, 342 
26, 30, 35, 37), replicon screening vectors (12), and expression vectors (40). However, 343 
the majority of these are based on poorly characterized replicons since the mode of 344 
replication has only been investigated in a small number of plasmids (4, 21, 27, 32). 345 
Indeed, apart from pBC1 (2), only the recently reported plasmid pCIBA089 from B. 346 
asteroides has been characterized at the molecular level (5). 347 
One of the key factors in vector development is the plasmid host range. A broad 348 
host range is necessary if genes are to be transferred among different species and 349 
genera, but a narrow host range is preferred to ensure the confinement of plasmid-350 
engineered traits (i.e., to prevent the dissemination of genes among competitors and 351 
harmful microorganisms inhabiting the same environment [6]). The ability of the pBC1 352 
replicon to replicate in a large number of bifidobacterial species, including the well-353 
known commercial probiotic strain B. animalis subsp. lactis Bb12 (Chr. Hansen A/S, 354 
Hørsholm, Denmark), renders pBC1-derivatives easily transferable among species of 355 
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this genus, in which they were found to show rather high segregation stability. 356 
Differences in the transformation efficiency among strains may be a result of different 357 
genetic backgrounds, and may be related to interference with integrated plasmid 358 
remnants (e.g., in B. longum NCC 2075) (42) or to the presence of 359 
restriction/modification systems (as in B. breve UCC 2003) (D. van Sinderen, personal 360 
communication). In fact, the transformation efficiency is better when the DNA of the 361 
constructs is isolated from bifidobacteria (Table 2). Alternatively, the transformation 362 
frequency might also be affected by a differential sensitivity of the strains to oxygen, as 363 
the preparation of electrocompetent cells demands excessive handling at open air. 364 
Although transformation frequencies are rather high for at least some strains, higher 365 
transformation frequencies are needed for most genetic purposes, and the improvement 366 
of current gene transfer systems or the development of new transformation strategies 367 
remains a necessity. 368 
The high relative copy number of pBC1 and its derived vectors (around 30 copies 369 
per chromosome equivalent) could complement pCIBA089-derivatives (approximately 370 
4 copies per cell) (5), allowing the fine tuning of gene expression through gene dosage. 371 
Further, the pBC1 replicon has proven to be non-functional in some bacterial species, 372 
including non-related Gram-positive (L. lactis, L. casei, E. durans,and P. acidilactici) 373 
and Gram-negative bacteria (E. coli), a prerequisite for the future development of food 374 
grade vectors. These, apart from the absence of antibiotic resistance genes, should 375 
preferably not replicate in bacteria from the same ecosystem in order of not to spread 376 
the (beneficial) properties, which might provide selective advantages to competitors (6). 377 
The fact that pAM4 could replicate in C. glutamicum is not surprising, as this bacterium 378 
belongs as the bifidobacteria to the phylum Actinobacteria, thus being phylogenetically 379 
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related. The replication of pBC1-derivatives in other Actinobacteria is currently being 380 
tested. 381 
The number of useful restriction enzymes in some of the vectors developed in this 382 
study are certainly limited (XbaI, SalI, PstI, SphI and HindIII in most of them). 383 
However, the availability of several complete genome sequences allows the easy 384 
cloning of PCR-amplified DNA fragments to which desired restriction enzyme sites can 385 
be added. The use of ligase-independent cloning methods, such as the recently 386 
developed PCR In-fusionTM technique (Clontech Lab. Inc., Palo Alto, CA) (13), would 387 
further allow the cloning of DNA fragments without the need of a large multi-cloning 388 
site (MCS). Nevertheless, one of the vectors, pAM5, has been endowed with a long 389 
MCS with more than 20 single restriction enzyme sites. The incorporation of the lacZα 390 
gene into pAM6 would further allow a convenient color screening (blue-white) for 391 
plasmids carrying inserts in E. coli. 392 
The mode of replication is another key factor in a vector, as it affects the structural 393 
stability, the host range, and the size of the DNA fragments that can successfully be 394 
cloned. In general, vectors that follow a theta type replication mechanism are preferred 395 
over those replicating by the RC mode; they are usually more stable, accept larger DNA 396 
fragments and have a narrower host range (7, 16). As mentioned, sequence comparisons 397 
and phylogenetic analyses have indicated that pBC1 might replicate via a theta-type 398 
mechanism. Based on sequence similarities, this mode of replication has only been 399 
suggested for the bifidobacterial plasmids pMB1 (35) and pDOJH10S (21) from B. 400 
longum, and more recently for pCIBAO89 and pCIBA43 from B. asteroides (5). 401 
Though the theta mode of replication has yet to be proved, the present study provides 402 
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further indications that pBC1 may use the theta type of replication since no ssDNA 403 
intermediates were detected during plasmid replication. 404 
Arabinofuranosidases are involved in the breakdown of many non-digestible (i.e., 405 
by humans) dietary carbohydrates by bifidobacteria (24). Therefore, this enzymatic 406 
activity is related to the utilization of non-digestible carbohydrates as fermentative 407 
prebiotic substrates for bifidobacteria. Engineering of probiotic strains with greater 408 
arabinofuranosidase activity might lead to a better competition of probiotic strains in the 409 
human GIT ecosystem and/or allow the future use of strain-specific prebiotics. In this 410 
example, by the use of a pBC1-derived vector, the specific activity of this enzyme was 411 
increased more than 100-fold from the low basal level of the untransformed B. 412 
pseudocatenulatum M115. The same α-arabinofuranosidase increase was observed 413 
respect to the activity of the original B. longum B667 grown in glucose, as its enzymatic 414 
activity seems to be subjected to induction by arabinose-containing substrates (11). The 415 
success of this experience suggests a great potential of these vectors for cloning and 416 
expressing desirable genes in bifidobacteria, and the feasibility of modifying strains of 417 
this commercially and medically important bacterial group. 418 
 419 
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Table 1.- Bacterial strains, plasmids and oligonucleotide primers utilized in this work. 518 
Item Genotype, phenotype or sequence Source or reference 
   
Strains   
Escherichia coli DH5α F
-
, φ80dlacZ∆M15, ∆(lacZYA-argF)U169, deoR, recA1, endA1, 
hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1 Invitrogen 
Escherichia coli DH11S mcrA, ∆(mrr-hsdRMS-mcrBC), ∆(lac-proAB), ∆(rec1398), deoR, rpsL, 
srl-thi-/F'proAB+ lacIqZ∆M15 Invitrogen 
Escherichia coli TOP10 F
-
mcrA, ∆(mrr-hsdRMS-mcrBC) F80lacZ∆M15, ∆lacX74, recA1, deoR, 
araD139, ∆(ara-leu)7697, galU, galK, rspL (StrR), endA1, nupG Invitrogen 
Bifidobacterium longum B667   Human intestinal plasmid-free strain; containing an α-L-
arabinofuranosidase gene Margolles and de los Reyes Gavilán (24) 
Bifidobacterium pseudocatenulatum M115 Human intestinal isolate, plasmid-free IPLA Laboratory Collection 
Bifidobacterium breve UCC2003 Human intestinal isolate, plasmid-free APC, University College Cork; Ireland 
Bifidobacterium dentium F101 Human intestinal isolate, plasmid-free IPLA Laboratory Collection 
Bifidobacterium longum L25 Human intestinal isolate, plasmid-free IPLA Laboratory Collection 
Bifidobacterium adolescentis LMG 10502 Human intestinal isolate, plasmid-free LMG, Universiteit Gent, Belgium 
Bifidobacterium animalis subsp. animalis LMG 10508 Human intestinal isolate, plasmid-free LMG 
Bifidobacterium animalis subsp. lactis Bb12 Commercial fermented milk IPLA Laboratory Collection 
Bifidobacterium breve LMG 13208 Human intestinal isolate, plasmid-free LMG 
Bifidobacterium thermophilus LMG 11571 Human intestinal isolate, plasmid-free LMG 
Bifidobacterium pseudolongum subsp. pseudolongum 
LMG 11571 Human intestinal isolate, plasmid-free LMG 
Corynebacterium glutamicum LMG 19741 Sewage LMG 
Pediococcus acidilactici LMG 11384 Barley LMG 
   
Plasmids   
pUC19 Apr, lacZα, general cloning vector, MCS with 11 restriction enzyme sites Yanisch-Perron et al. (55) 
pUK21 Apr, lacZα, general cloning vector, MCS with 28 restriction enzyme sites Vieira and Messing (52) 
pCR®4-TOPO Apr, lacZα, TA cloning vector Invitrogen, Carlsbad, CA, USA 
pAM1 E. coli-Bifidobacterium shuttle cloning vector; Apr, Emr Álvarez-Martín et al. (1) 
pAM2 Bifidobacterium cloning vector; Emr Álvarez-Martín et al. (1) 
pAM3 E. coli-Bifidobacterium shuttle cloning vector; Apr, Emr, Tetr [tet(W)] This work 
pAM4 E. coli-Bifidobacterium shuttle cloning vector; Apr, Tetr [tet(W)] This work 
pAM-abfB α-L-arabinofuranosidase gene in pAM1; Apr, Emr This work 
   
Oligonucleotides (5’-3’)   
Fxfp GACGTCACCAACAAGCAGTG Álvarez-Martín et al. (1) 
Rxfp CTTCCATCTGGTGCTCGGAG Álvarez-Martín et al. (1) 
FrepB GCCACGTTCGTCGCCATCCA Álvarez-Martín et al. (1) 
RrepB CCGACCAGCTCTGCCTTTTG Álvarez-Martín et al. (1) 
LacZF CGTATGTTGTGTGGAATTGTGAG This work 
LacZR GAAATACCGCACAGATGCGTAAG This work 
tet(W)-SacIF CCCTGGAGCTCATGCTCATCATGTAC This work 
 27 
tet(W)-SacIR CCATCGGAGCTCCATAACTTCTG This work 
abfBF-SphI (α-L-arabinofuranosidase gene) CGAATCCCGCATGCGTACGAGGCAGTGTGGAATCC This work 
abfBR-PstI (α-L-arabinofuranosidase gene) TGTTCGCGCTGCAGGCTTCGATGACGTGGAGGAATC This work 
   
Apr, Emr, and Tetr, resistance to ampicillin, erythromycin, and tetracycline, respectively. 518 
Underlined oligonucleotide sequences show artificial restriction enzyme sites introduced for cloning. 519 
MCS, multiple cloning site 520 
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Table 2.- Host range and transformation frequencies of pBC1-derived vectors. 
 
Transformants per µg of DNA Species and strain 
pAM1 pAM2a pAM4 
    
B. adolescentis LMG 10502 - - 9.2x102 
B. animalis subsp. animalis LMG 10508 - - 4.0x101 
B. animalis subsp. lactis Bb12 - - 1.6x102 
B. breve LMG 13208 - - 1.0x102 
B. breve UCC 2003 2.3x102 6.4x104 1.4x102 
B. dentium F101 - - 9.5x101 
B. longum L25 - - 6.6x101  
B. pseudolongum subsp. pseudolongum LMG 11571  - - 6.3x101  
B. pseudocatenulatum M115 2.5x105 8.3x105 1.0x105 
B. thermophilus LMG 11571 - - 4.6x101 
    
Corynebacterium glutamicum LMG 19741 - - 3.0x100 
    
Enterococcus durans L72 - - 0 
Lactobacillus casei ATCC 393 - - 0 
Lactococcus lactis subsp. cremoris MG 1363 0 0 0 
Lactococcus lactis subsp. lactis IL1403 - 0 0 
Pediococcus acidilactici LMG 11384 - - 0 
    
Escherichia coli DH5α - 0 - 
    
 
a
 Whenever possible, pAM2 DNA was isolated from the same strain to which is was 
transformed. 
-, not done or not applicable. 
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FIGURE LEGENDS 522 
 523 
Figure 1. Physical maps of the plasmids utilized and the constructs obtained in this work 524 
from the pBC1 replicon. The color key tracks the origin, length and direction of the open 525 
reading frames (ORFs) and other structures, as indicated. Only relevant restriction enzyme 526 
sites are indicated. Molecules are proportional but not drawn to scale. MCS, multiple 527 
cloning site. 528 
 529 
Figure 2.- Hybridization experiments aimed to analyze pBC1 replication intermediates 530 
using as probes internal segments of repB genes from pBC1 from B. catenulatum and 531 
pBM02 from Lactococcus lactis (positive control for the detection of ssDNA) (36). Panels 532 
A and C. Ethidium bromide stained gels showing total DNA preparations from B. 533 
pseudocatenulatum M115 harboring construct pBC1.2 (8.0 kpb) (lanes 1 and 5); B. 534 
pseudocatenulatum M115 carrying construct pBC1.5 (8.7 kpb) (lanes 2 and 6); B. 535 
catenulatum L48 containing the original pBC1 plasmid (2.5 kbp) (lanes 3 and 7); E. coli 536 
DH5α carrying construct p210 from L. lactis (3.8 kbp) (lanes 4 and 8). M, molecular 537 
weight marker. Plasmids were isolated before (N) and after incubation of the cells for one h 538 
with both rifampicin and chloramphenicol or erythromycin (R). Panel B. Autoradiogram 539 
after hybridization of a gel transferred under non-denaturing conditions (which favors the 540 
transfer of ssDNA). Panel D. Autoradiogram after hybridization of a gel transferred under 541 
denaturing conditions. The position of ssDNA of plasmid p210 from L. lactis in the sample 542 
treated with rifampicin and chloramphenicol (Panels B and D, lane 8) is indicated.  543 
. 544 
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 522 
Figure 3.- Amplification and cloning of the α-L-arabinofuranosidase gene abfB from 523 
Bifidobacterium longum B667 and cloning in pAM1. Molecules are proportional but not 524 
drawn to scale. 525 
